AI English summary of an SEC filing — figures as filed

The company said on August 15, 2024 that it expanded its board to 11 members and appointed Christopher DelOrefice as a director. His term runs until the annual meeting on November 21, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Aug 16, 2024Period of report Aug 15, 2024Summary published (UTC) Oct 29, 2026

Key points

AI summary

The company said on August 15, 2024 that it expanded its board to 11 members and appointed Christopher DelOrefice as a director. His term runs until the annual meeting on November 21, 2024.
The company said DelOrefice has served as executive vice president and chief financial officer of Becton Dickinson and Company since September 2021. Previously, he was Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021.
ResMed said DelOrefice will serve on its audit committee. As a non-executive director, he will participate in the director compensation program on a pro rata basis.
The company said DelOrefice was not selected under any arrangement or understanding with another person, and it is not aware of any transactions with him that would require disclosure under Item 404(a). It also said it is entering into its standard indemnification agreement with him.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

ResMed Expands Board to 11 Members, Appoints Christopher DelOrefice

The company said on August 15, 2024 that it expanded its board to 11 members and appointed Christopher DelOrefice as a director. His term runs until the annual meeting on November 21, 2024.

Source · Based on the filing body and exhibits

DelOrefice's Current Role and Prior Experience

The company said DelOrefice has served as executive vice president and chief financial officer of Becton Dickinson and Company since September 2021. Previously, he was Vice President, Investor Relations at Johnson & Johnson from August 2018 to September 2021.

Source · Based on the filing body and exhibits

Audit Committee Role and Director Pay

ResMed said DelOrefice will serve on its audit committee. As a non-executive director, he will participate in the director compensation program on a pro rata basis.

Source · Based on the filing body and exhibits

Appointment-Related Agreements and Indemnification

The company said DelOrefice was not selected under any arrangement or understanding with another person, and it is not aware of any transactions with him that would require disclosure under Item 404(a). It also said it is entering into its standard indemnification agreement with him.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.